Future drug targets for Parkinson's disease;Futures pistes thérapeutiques médicamenteuses pour la maladie de Parkinson

Bulletin de l'Academie Nationale de Medecine

Volumn 196, Issue 7, 2012, Pages 1369-1379

  Hirsch, Etienne C ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Accidental falls; Dopamine; Inflammation; Parkinson disease

Indexed keywords

EID: 84878874817     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)31718-2     Document Type: Article

References (27)

1. Braak H., Bohl J.R., Mû̈llerC.M., Rüb U., De Vos R.A.I., DelTredici K. -Stanley Fahn Lecture 2005: The staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov. Disord., 2006,21(12), 2042-51.
2. McKeith I., Dickson D., Lowe J., Emre M., O'Brien J., Feldman H. et al. - Dementia with Lewy bodies: diagnosis and management: Third report of the DLB Consortium. Neurology, 2005,65, 1863-72.
3. Hirsch E.C., Mouatt A., Faucheux B., Bonnet A.M., Javoy Agid F., Graybiel A.M., Agid Y. - Dopamine, tremor and Parkinson's disease. Lancet, 1992,340, 125-126.
4. Hirsch E.C., Graybiel A.M., Agid Y. - Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Nature, 1988,334, 345348.
5. Obeso J.A., Rodriguez-Oroz M.C., Goetz C.G. et al. - Missing pieces in the Parkinson's disease puzzle. Nat. Med, 2010,16, 653-61.
6. Salazar J., Mena N., Hunot S. et al. - Divalent Metal Transporter 1 (DMT1) contributes to neurodegeneration in parkinsonian syndromes. Proc. Natl. Acad Sci. U.S.A., 2008, 105, 18578-18583.
7. Steiner J.A, Angot E., Brundin P. - A deadly spread: cellular mechanisms of α-synuclein transfer. Cell Death Differ. 2011, 75, 1425-1433.
8. Hôglinger G.U., Carrard G., Michel P.P. et al. - Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease. J. Neurochem., 2003,86, 1297-1307.
9. Anglade P., Vyas S., Javoy Agid F. et al. - Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. and Histopathol, 1997, 12, 25 31.
10. Hartmann A., Hunot S., Michel P.P. et al. - Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad. Sci. U.S.A., 2000, 97, 2875-2880.
11. Hartmann A., Troadec J.-D., Hunot S. et al. - Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J. Neurosci, 2001,21, 2247-2255.
12. Hirsch E.C., Hunot S. - Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol. 2009,8, 382-397.
13. Nagatsu T., Mogi M., Ichinose H., Togari A. - Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural. Transm. Suppl, 2000,60, 277-290.
14. Teismann P., Tieu K., Choi D.K. et al. - Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad Sci. USA. 2003,100, 5473-5478.
15. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C. - Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglita-zone in a mouse model of Parkinson's disease. J. Neurochem., 2002, 82, 615-624.
16. Brochard V., Combadiere B., Prigent A. et al. - Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009,119, 182-192.
17. Reynolds A.D., Stone D.K., Mosley R.L., Gendelman H.E. - Nitrated {alpha}-synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. J. Immunol, 2009, 752,4137-4149.
18. Schapira A.H. - Progress in neuroprotection in Parkinson's disease. Eur. J. Neurol. 2008,15 Suppl. 1, 5-13.
19. Ros-Bernal F., Hunot S., Herrero M.T. et al. - Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl. Acad Sci. USA, 2011,108, 6632-6637.
20. Rascol O., Fitzer-Attas C.J., Hauser R. et al. - A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol.,2011,10, 415-423.
21. Kempster P.A., O'Sullivan S.S., Holton J.L., Revesz T., Lees A.J. - Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain, 2010,133, 1755-1762.
22. Hoehn M., Yahr M. - Parkinsonism: onset, progression and mortality. Neurology, 1967,17, 427-442.
23. Lopez I.C., Ruiz P.J., Del Pozo S.V., Bernardos V.S. - Motor complications in Parkinson's disease: ten year follow-up study. Mov. Disord., 2010,25, 2735-2739.
24. Karachi C, Grabli D., Bernard FA. et al. - Cholinergic mesencephalic neurons are involved in gait and postural disorders in parkinsonian patients and monkeys. J. Clin. Invest., 120,2745-54, 2010.
25. Hirsch E., Graybiel A.M., Duyckaerts C, Javoy Agid F. - Neuronal loss in the peduncu-lopontine tegmental nucleus in Parkinson's disease and in progressive supranuclear palsy. Proc Natl. Acad. Sci. U.S.A., 1987, 84, 5976-5980.
26. Mazzone P., Lozano A., Stanzione P. et al. - Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. Neuroreport., 2005, 16, 1877-1881.
27. Ferraye M.U., Debû B., Fraix V. et al. - Subthalamic nucleus versus pedunculopontine nucleus stimulation in Parkinson disease: synergy or antagonism? J. Neural. Transm., 2011,118, 1469-1475.